Stephanie Royer‐Joo

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C Mutation

Adrian G. Sacher, Patricia LoRusso, Manish R. Patel et al. · New England Journal of Medicine · 2023 · 294 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek et al. · Journal for ImmunoTherapy of Cancer · 2018 · 152 citations · Full text

Medicine, Oncology, Pharmacology +9

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

Jayesh Desai, Guzmán Alonso, Se Hyun Kim et al. · Nature Medicine · 2023 · 122 citations · Full text

Medicine, Oncology, Pharmacology +17

A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Zev A. Wainberg, Wells A. Messersmith, Parvin F. Peddi et al. · Clinical Colorectal Cancer · 2013 · 59 citations

Medicine, Oncology, Pharmacotherapy +12

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

Joyce F. Liu, Howard A. Burris, Judy S. Wang et al. · Gynecologic Oncology · 2021 · 56 citations · Full text

Pharmacy, Oncology, Pharmacology +16